Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6
Information source: National Institute on Drug Abuse (NIDA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cocaine-Related Disorders
Intervention: Baclofen (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Walter Ling, M.D., Principal Investigator, Affiliation: Friends Research Institute, Inc.
Summary
The purpose of this study is to empirically test a series of medications to: 1) determine
each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective
dose range for each medication. In this study, baclofen is tested.
Clinical Details
Official title: Rapid Evaluation of Cocaine Pharmacotherapies (Baclofen)
Study design: Treatment, Randomized, Double-Blind, Placebo Control
Primary outcome: RetentionCocaine use Cocaine craving Psychosocial progress
Detailed description:
16-week participation plus a 2 week lead in period. Participants are assigned randomly to
placebo or baclofen. Participant attend group meetings 3 x/week.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
M/F ages 18-65. cocaine dependence according to DSM-IV criteria. Self-reported use within
the last 30 days. Agreeable to conditions of study and signed informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy, history of seizures, pregnant and/or
nursing women, dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acute
hepatitis. Other medical conditions that deem participation to be unsafe.
Locations and Contacts
Friends Research Institute, Los Angeles, California 90025, United States
Additional Information
Starting date: October 1997
Last updated: August 16, 2005
|
